AQR Capital Management
CNCE

AQR Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

AQR Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-47,245
Closed -$199K – 2366
2021
Q2 		$199K Sell
47,245
-23,994
-34% -$102K ﹤0.01% 2145
2021
Q1 		$355K Buy
+71,239
New +$576K ﹤0.01% 1958
2020
Q1 		– Sell
-13,648
Closed -$126K – 2195
2019
Q4 		$126K Buy
+13,648
New +$96.7K ﹤0.01% 2062
2019
Q2 		– Sell
-25,240
Closed -$305K – 2221
2019
Q1 		$305K Sell
25,240
-99,154
-80% -$1.46M ﹤0.01% 1968
2018
Q4 		$1.56M Sell
124,394
-119,687
-49% -$1.65M ﹤0.01% 1341
2018
Q3 		$3.62M Sell
244,081
-25,107
-9% -$395K ﹤0.01% 1136
2018
Q2 		$4.53M Sell
269,188
-118,560
-31% -$2.3M ﹤0.01% 1075
2018
Q1 		$8.88M Buy
387,748
+225,009
+138% +$5M 0.01% 804
2017
Q4 		$4.21M Buy
+162,739
New +$3.28M ﹤0.01% 1097
2016
Q4 		– Sell
-15,125
Closed -$153K – 2297
2016
Q3 		$153K Sell
15,125
-22,344
-60% -$244K ﹤0.01% 2194
2016
Q2 		$421K Sell
37,469
-29,317
-44% -$373K ﹤0.01% 1927
2016
Q1 		$912K Sell
66,786
-41,490
-38% -$597K ﹤0.01% 1611
2015
Q4 		$2.05M Sell
108,276
-49,805
-32% -$1.08M ﹤0.01% 1226
2015
Q3 		$2.97M Buy
158,081
+126,582
+402% +$2.15M 0.01% 972
2015
Q2 		$469K Buy
+31,499
New +$480K ﹤0.01% 1813

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AQR Capital Management's CNCE Position: Q3 2021 in Review

AQR Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2021, closing a stake of 47,245 shares — an estimated $199K sold.

AQR Capital Management first reported a position in CNCE in Q2 2015 and held it in 15 quarters. The position peaked at $8.88M in Q1 2018. 61 funds tracked by Wall St. Rank hold CNCE as of Q3 2021.

  • AQR Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • AQR Capital Management sold 47,245 Concert Pharmaceuticals, Inc. shares in Q3 2021, an estimated $199K.
  • AQR Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2015 and held it in 15 quarters.
  • AQR Capital Management's Concert Pharmaceuticals, Inc. position peaked at $8.88M in Q1 2018.
  • 61 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2021.

Based on AQR Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.